Berkshire Hathaway Chairman and CEO Warren Buffett
Yesterday, Warren Buffett, the chairman and CEO of Berkshire Hathaway Inc. (NYSE: BRK.A; BRK.B), said he thinks the United States will “work fine” under President Donald Trump.
His reason: America’s got the “secret sauce” – the ability to survive.
“America works,” Buffett told CNBC on Thursday (Jan. 19). “I’ve said this before. It’ll work wonderfully under [former Democratic presidential candidate] Hillary Clinton, and I think it’ll work fine under Donald Trump.”
The billionaire also conceded that he doesn’t think the United States works perfectly, “but you just look at where we go, milestone after milestone. Never bet against America.”
Buffett likewise took the CNBC interview yesterday as an opportunity to reiterate his call to invest now for the long haul…
Top 5 Warren Buffett Stocks To Own For 2018: Snap-On Incorporated(SNA)
- [By WWW.MONEYSHOW.COM]
Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.
- [By WWW.THESTREET.COM]
Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?
- [By John Divine]
Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.
That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.
As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter.
Top 5 Warren Buffett Stocks To Own For 2018: Popeyes Louisiana Kitchen, Inc.(PLKI)
- [By Daniel Miller]
While chicken and burgers might not sound like a match made in heaven for dinner, it could be tasty for investors inRestaurant Brands International (NYSE:QSR). The parent company of Burger King agreed to purchase Popeyes Louisiana Kitchen Inc. (NASDAQ:PLKI).
- [By Monica Gerson]
Popeyes Louisiana Kitchen Inc (NASDAQ: PLKI) is estimated to post its quarterly earnings at $0.64 per share on revenue of $85.31 million.
SpartanNash Co (NASDAQ: SPTN) is expected to post its quarterly earnings at $0.49 per share on revenue of $2.28 billion.
- [By Ashley Moore]
Popeyes Louisiana Kitchen Inc. (Nasdaq: PLKI) stock is up 19% today (Tuesday) after Burger King’s parent company, Restaurant Brands International Inc. (NYSE: QSR), announced it will buy the fast-food chicken company.
Top 5 Warren Buffett Stocks To Own For 2018: Cummins Inc.(CMI)
- [By WWW.THESTREET.COM]
There are lots of stories like that out there these days. People were perplexed about the Illinois Tool Works (ITW) and Cummins Engine (CMI) and Caterpillar (CAT) quarters, but they turned out to be classic buying opportunities after years of being sell opportunities if the stocks had run. I can’t explain to you how amazing that is. Here are three stocks that have spent months and months in purgatory when they have missed or guided down or slashed forecasts. Now they are up gigantically.
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , Paccar (PCAR) , Cummins (CMI) , ConocoPhillips (COP) , Adobe Systems (ADBE) , Annaly Capital (NLY) and Hewlett Packard Enterprise (HPE) .
- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close Friday was Cummins Inc. (NYSE: CMI) which traded down about 5% at $159.44. The stocks 52-week range is $134.06 to $181.79. Volume was over 3.5 million versus the daily average of 1.2 million shares.
- [By Reuben Gregg Brewer]
Making mining equipment has been a horrible business over the last few years. The industry has been hard-hit by the spending cutbacks at mine sites around the world. For example, BHP Billiton Limited trimmed its capital exploration expenditures by roughly 70% between fiscal 2013 and 2016. No wonder Caterpillar Inc. (NYSE:CAT), Komatsu Ltd. (NASDAQOTH:KMTUY), and Cummins Inc. (NYSE:CMI) have been hurting. Only that looks like it’s starting to change, which means this trio could be at the top of a list of mining equipment companies to buy in 2017.
- [By Reuben Gregg Brewer]
Ever walk past a construction site? It’s hard not to be enthralled by all the heavy construction machinery moving things around. With the world’s developing economies still building at a relatively fast pace and developing economies, like the United States, in desperate need of upgrading their aging infrastructure, the companies behind that construction machinery could be just as exciting as a construction site in the years ahead. Which is why Caterpillar Inc. (NYSE:CAT), Cummins Inc. (NYSE:CMI), and Terex Corporation (NYSE:TEX) are three of the top construction machinery stocks to look at right now.
Top 5 Warren Buffett Stocks To Own For 2018: Tele Celular Sul Participacoes S.A.(TSU)
- [By Lisa Levin]
In trading on Monday, telecommunications services shares fell 0.45 percent. Meanwhile, top losers in the sector included Shenandoah Telecommunications Company (NASDAQ: SHEN), down 3 percent, and TIM Participacoes SA (ADR) (NYSE: TSU) down 2 percent.
Top 5 Warren Buffett Stocks To Own For 2018: Eli Lilly and Company(LLY)
- [By Dimitra DeFotis]
Shares of Eli Lilly (LLY) are down nearly 13% this morning after a late-stage Alzheimer’s drug trial failed to produce expected results.
Biogen(BIIB), down nearly 6% today, also is working on an Alzheimer’s treatment; Merck (MRK) shareswere down 1% in recent trading.
Lilly was testing the drug as a treatment for mild dementia due to Alzheimer’s disease.Credit Suisse analysts were hopeful the drug trial would show “a statistically significant impact on cognition.”MarketWatch reports:
“Eli Lilly said it would not pursue approval for the drug to treat mild dementia due to Alzheimers disease and that it will ‘evaluate the impact of these results on the development plans for solanezumab and our other Alzheimers pipeline assets’ … More specifics about the solanezumab drug, expected the night of Dec. 9 during a meeting of the Clinical Trials on Alzheimers Disease (CTAD), could have repercussions for whats called the beta amyloid hypothesis in Alzheimers disease treatments, which target protein fragments that some believe are responsible for the disease …”
On Nov. 15, J.P. Morgan analysts Chris Schott, Aditi Singhania, Dana Flanders and Christopher Neyor noted that trial success had a low probability. But they kept their$95 price target on the stock, noting the drug pipeline offers other opportunities. Their target implies upside of more than 40% from a recent price near $66. They wrote:
“… On solanezumab … While the FDA recommends both cognitive and function endpoints for Alzheimers drug approvals, we expect the agency to review solanezumab on the totality of evidence, and we would not be surprised to see a cognitive benefit coupled with a trend in secondary functional endpoints be sufficient for approval … regardless of the solanezumab outcome, we see a diverse range of new product opportunities supporting LLY
- [By Johanna Bennett]
Eli Lilly & Co. (LLY) and Biogen (BIIB) are far from the only two drug makers racing to deliver a new treatment for Alzheimers disease. But they are pretty much leading the pack.
The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industrys version of the holy grail.
And according to Barclays analysts Geoff Meacham and Paul Choi, the next few weeks could prove to be one of the most fertile periods in Alzheimers disease research since 2008.
We think the most likely outcome for Lilly’s Phase 3 EXPEDITION 3 (E3) solanezumab trial is the primary cognition (ADAS-Cog14) endpoint is met (just achieving statistical significance with a p-value <0.05) and mixed results on the secondary endpoints including function (ADL), which we believe should be good enough to support a regulatory submission. While aducanumab has a marginally different mechanism of action, we nevertheless expect BIIB shares to trade in sympathy to Lilly.
Implications for Biogen and Merck: The E3 results are likely to result in volatility for Biogen (up 20-30%, down 10-15%) as Alzheimer’s drives both long-term growth and M&A value even though aducanumab works differently from solanezumab.
Aducanumab dose titration data is expected at the CTAD meeting (San Diego, Dec. 9). Merck’s Phase 2/3 EPOCH verubecestat (BACE) trial is scheduled to finish in June 2017 but unlike E3, PET scans/CSF tests for A were not an inclusion criteria. We think Merck shares could move 3% to 5% in either direction in sympathy to E3.
At $76.58, Lillys share price has fallen more than 9% over the past year, while Biogen has climbed more than 9% over the same span.
- [By Maxx Chatsko]
Both Evenity and Tymlos are anabolic treatments, which means they encourage bone growth, rather than merely preventing bones from becoming more brittle, as prior generation osteoporosis drugs have done. While Eli Lilly (NYSE:LLY) was the first to market a drug in this class when Forteo gained marketing approval in 2002, it has faced no competitors despite achieving $1.5 billion in global sales last year, including $770 million in the United States. All of its patents expire by August 2019.
- [By Keith Speights]
With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.
- [By David Zeiler]
Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.